Prognostic impact of circulating interleukin 6 levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A subgroup analysis from the AUTENTIC study


Por: Kareaga, MM, Paul, AM, Echebarria, ID, Arrula, VA, Sanchez, LT, Brun, LP, Davila, L, Etxebarria, II, Ibarbia, MA, Mediavilla, JG, Ruiz, IM, Garcia, IG and Bujanda, IL

Publicada: 1 nov 2025 Ahead of Print: 1 nov 2025
Resumen:


Filiaciones:
Kareaga, MM:
 HUA Hosp Univ Araba Txagorritxu, Med Oncol Dept, Vitoria, Spain

Paul, AM:
 Hosp Galdakao Usansolo, Med Oncol Dept, Galdakao, Spain

Echebarria, ID:
 Hosp Univ Donostia, Dept Oncol, San Sebastian, Spain

Arrula, VA:
 Royal Navarre Hosp, Med Oncol, Complejo Hosp Navarra, Pamplona, Spain

Sanchez, LT:
 Royal Navarre Hosp, Med Oncol, Complejo Hosp Navarra, Pamplona, Spain

:
 Hosp Mataro Consorcio Sanitario Maresme, Med Oncol, Mataro, Spain

Davila, L:
 Hosp Univ San Pedro, Med Oncol, Logrono, Spain

Etxebarria, II:
 HUA Hosp Univ Araba Txagorritxu, Med Oncol, Vitoria, Spain

Ibarbia, MA:
 Hosp Galdakao Usansolo, Med Oncol, Galdakao, Spain

Mediavilla, JG:
 Onkologiko Donostia Kutxa Fundaz, Med Oncol, San Sebastian, Spain

Ruiz, IM:
 Royal Navarre Hosp, Oncol Dept, Complejo Hosp Navarra, Pamplona, Spain

Garcia, IG:
 HUA Hosp Univ Araba Txagorritxu, Med Oncol, Vitoria, Spain

Bujanda, IL:
 Royal Navarre Hosp, Internal Med, Complejo Hosp Navarra, Pamplona, Spain
ISSN: 09237534





Annals of Oncology
Editorial
Oxford University Press, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Reino Unido
Tipo de documento: Meeting Abstract
Volumen: 36 Número:
Páginas:
WOS Id: 001641342400073

MÉTRICAS